糖尿病性视网膜病变
体内
药理学
Zeta电位
壳聚糖
渗透
药物输送
离体
药品
超声
医学
抗癌药
体外
眼科
化学
糖尿病
纳米技术
色谱法
材料科学
生物化学
纳米颗粒
内分泌学
有机化学
生物
生物技术
膜
作者
Deep Shikha Sharma,Sheetu Wadhwa,Monica Gulati,Bimlesh Kumar,Nitin Chitranshi,Vivek Gupta,Mohammed Alrouji,Sharif Alhajlah,Othman AlOmeir,Sukriti Vishwas,Rubiya Khursheed,Sumant Saini,Ankit Kumar,Shaik Rahana Parveen,Gaurav Gupta,Flavia C. Zacconi,Dinesh Kumar Chellappan,Andrew Morris,Raimar Löebenberg,Kamal Dua,Sachin Kumar Singh
标识
DOI:10.1016/j.ijbiomac.2022.10.168
摘要
Diabetic retinopathy (DR) is one of the chronic complications of diabetes. It includes retinal blood vessels' damage. If untreated, it leads to loss of vision. The existing treatment strategies for DR are expensive, invasive, and need expertise during administration. Hence, there is a need to develop a non-invasive topical formulation that can penetrate deep to the posterior segment of retina and treat the damaged retinal vessels. In addition, it should also provide sustained release. In recent years, novel drug delivery systems (NDDS) have been explored for treating DR and found successful. In this study, chitosan (CS) modified 5-Fluorouracil Nanostructured Lipid Carriers (CS-5-FU-NLCs) were prepared by modified melt emulsification-ultrasonication method and optimized by Box-Behnken Design. The size, polydispersity index, zeta potential and entrapment efficiency of CS-5-FU-NLCs were 163.2 ± 2.3 nm, 0.28 ± 1.52, 21.4 ± 0.5 mV and 85.0 ± 0.2 %, respectively. The in vitro drug release and ex vivo permeation study confirmed higher and sustained drug release in CS-5-FU-NLCs as compared to 5-FU solution. HET-CAM Model ensured the non-irritant nature of CS-5-FU-NLCs. In vivo ocular studies of CS-5-FU-NLCs confirmed antiangiogenic effect of 5-FU by CAM model and diabetic retinopathy induced rat model, indicating successful delivery of 5-FU to the retina.
科研通智能强力驱动
Strongly Powered by AbleSci AI